RAPT Therapeutics Inc (RAPT)
2.72
-0.07
(-2.51%)
USD |
NASDAQ |
Jul 03, 16:00
RAPT Therapeutics Research and Development Expense (Annual): 101.00M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 101.00M |
| December 31, 2022 | 67.08M |
| December 31, 2021 | 56.98M |
| December 31, 2020 | 45.48M |
| Date | Value |
|---|---|
| December 31, 2019 | 34.91M |
| December 31, 2018 | 31.77M |
| December 31, 2017 | 25.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
34.91M
Minimum
2019
101.00M
Maximum
2023
61.09M
Average
56.98M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Ironwood Pharmaceuticals Inc | 116.08M |
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| Skye Bioscience Inc | 5.820M |
| Allakos Inc | 150.91M |
| X4 Pharmaceuticals Inc | 72.02M |